Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Inclusion Criteria: * Subjects greater than or equal to (\>=) 18 years of age with locally advanced unresectable or metastatic pancreatic adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than: * Radiosensitizing doses of 5-fluorouracil; * Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine; * Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical resection; * Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy * Subjects may have measurable or non-measurable disease according to RECIST 1.1. * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 * Acceptable hematological status, liver and renal function as defined in the protocol * Other protocol defined inclusion criteria could apply Exclusion Criteria: * Significant cardiac or peripheral vascular arterial disease * Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months) * Severe chronic obstructive or other pulmonary disease with hypoxemia * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Subjects receiving concomitant treatment with radiotherapy or other investigational drugs * Other protocol defined exclusion criteria could apply